Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Argus Health
Chubb
Fuji
QuintilesIMS
Citi
Colorcon
Express Scripts
Covington
US Army

Generated: October 21, 2017

DrugPatentWatch Database Preview

REXULTI Drug Profile

« Back to Dashboard

Which patents cover Rexulti, and when can generic versions of Rexulti launch?

Rexulti is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-nine patent family members in twenty-five countries.

The generic ingredient in REXULTI is brexpiprazole. Two suppliers are listed for this compound. Additional details are available on the brexpiprazole profile page.

Summary for Tradename: REXULTI

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list25
Clinical Trials: see list1
Patent Applications: see list37
Drug Prices:see details
DailyMed Link:REXULTI at DailyMed

Pharmacology for Tradename: REXULTI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-006Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-006Jul 10, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-001Jul 10, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-004Jul 10, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-005Jul 10, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-002Jul 10, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-001Jul 10, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-003Jul 10, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-004Jul 10, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-002Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: REXULTI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,206,167Piperazine-substituted benzothiophenes for treatment of mental disorders► Subscribe
9,480,686Piperazine-substituted benzothiophenes for treatment of mental disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: REXULTI

Country Document Number Estimated Expiration
Australia2006237905► Subscribe
Austria496911► Subscribe
Japan2006316052► Subscribe
World Intellectual Property Organization (WIPO)2006112464► Subscribe
Mexico2007012626► Subscribe
BrazilPI0609785► Subscribe
South Korea100937623► Subscribe
Malaysia142746► Subscribe
Russian Federation2007142023► Subscribe
India855DEN2012► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
Colorcon
UBS
Novartis
Boehringer Ingelheim
US Department of Justice
Cerilliant
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot